Natco Pharma Ltd

natcopharma.co.in BSE: 524816 NSE : NATCOPHARM

About [ edit ]

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. ^#
NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.^#

Key Points [ edit ]

Exports of formulations - Complex Generics (51% of sales)
Differentiated approach of manufacturing hard-to-make complex generic drugs including Para IV filings and FTF opportunities

US formulations have grown from 113 Cr in FY16 to 783 Cr in FY20 on the back of complex generic launches of drugs like copaxone, tamiflu, doxil and fosrenol.

Have a very rich pipeline of Para IV filings in US ^# with large contributions expected from drugs like Revlimid ($8bn market size; to be launched in FY23 ^#), Imbruvica ($4bn market size; currently under litigation ^#), and Pomalyst ($1.4bn market size; expected launch in 2025 ^#).

Other International markets mainly comprise sales in Canada and Brazil. ^# Canada sales has grown from 74 Cr in FY18 to 128 Cr in FY20, and Brazil sales has grown to 39 Cr in FY20.

Website BSE NSE

Market Cap ₹ 16,911 Cr.
Current Price ₹ 927
High / Low ₹ 996 / 572
Stock P/E 35.1
Book Value ₹ 223
Dividend Yield 0.73 %
ROCE 14.4 %
ROE 12.7 %
Face Value ₹ 2.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 22.07%

Cons

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020
	768	539	544	557	456	492	486	482	455	563	802	355
	384	321	323	348	307	301	351	354	326	392	526	273
Operating Profit	383	218	220	208	148	191	134	129	128	171	276	82
OPM %	50%	40%	41%	37%	33%	39%	28%	27%	28%	30%	34%	23%
Other Income	20	36	40	23	31	21	33	31	22	19	26	31
Interest	3	3	5	6	5	6	6	5	4	4	3	3
Depreciation	18	18	20	21	22	22	22	25	30	28	29	30
Profit before tax	382	232	235	205	152	184	139	129	117	158	271	80
Tax %	22%	22%	23%	22%	21%	22%	16%	19%	20%	23%	25%	21%
Net Profit	300	182	182	160	121	143	119	104	94	123	202	63
EPS in Rs	16.26	9.84	9.84	8.67	6.61	7.88	6.54	5.75	5.17	6.74	11.11	3.44
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	TTM
	444	457	460	524	661	739	825	1,042	2,020	2,185	2,094	1,915	2,176
	363	366	364	414	512	560	615	777	1,337	1,256	1,300	1,332	1,517
Operating Profit	81	91	96	109	149	179	210	266	683	928	795	583	658
OPM %	18%	20%	21%	21%	23%	24%	25%	25%	34%	42%	38%	30%	30%
Other Income	5	5	-1	9	2	17	0	12	14	40	130	107	98
Interest	15	15	14	23	26	37	32	23	18	15	19	22	13
Depreciation	14	20	16	16	22	30	47	51	54	66	81	100	117
Profit before tax	57	62	65	80	102	129	132	204	624	887	825	569	626
Tax %	20%	22%	20%	26%	36%	24%	1%	24%	22%	22%	22%	19%
Net Profit	44	49	54	60	72	103	135	157	486	696	644	461	482
EPS in Rs	3.14	3.46	3.80	3.83	4.58	6.21	8.10	9.02	27.88	37.74	35.24	25.31	26.46
Dividend Payout %	8%	12%	11%	16%	17%	16%	12%	14%	24%	22%	18%	27%

Compounded Sales Growth
10 Years:	15%
5 Years:	18%
3 Years:	-2%
TTM:	14%

Compounded Profit Growth
10 Years:	25%
5 Years:	28%
3 Years:	-2%
TTM:	-1%

Stock Price CAGR
10 Years:	33%
5 Years:	16%
3 Years:	5%
1 Year:	59%

Return on Equity
10 Years:	20%
5 Years:	21%
3 Years:	19%
Last Year:	13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Sep 2020
	28	28	28	31	31	33	33	35	35	37	36	36	36
Reserves	230	278	324	442	502	693	813	1,261	1,614	3,035	3,452	3,737	4,029
Borrowings	126	120	220	259	338	240	312	113	222	173	386	316	434
	142	129	135	173	209	229	226	413	446	470	428	498	606
Total Liabilities	526	554	707	905	1,080	1,196	1,384	1,822	2,318	3,715	4,303	4,588	5,106
	234	262	270	320	583	645	710	710	833	1,019	1,227	1,584	1,685
CWIP	47	40	76	164	106	124	129	212	336	480	638	518	454
Investments	34	61	63	63	2	2	2	22	32	76	169	112	301
	210	192	299	359	389	425	543	878	1,116	2,140	2,270	2,373	2,666
Total Assets	526	554	707	905	1,080	1,196	1,384	1,822	2,318	3,715	4,303	4,588	5,106

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
	61	75	37	65	61	144	93	112	346	464	669	417
	-74	-61	-89	-125	-111	-108	-120	-176	-299	-1,116	-611	-175
	16	-34	77	63	26	-35	29	154	-48	651	-51	-251
Net Cash Flow	3	-20	25	3	-24	0	2	90	-1	-2	7	-8

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2009	Mar 2010	Mar 2011	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020
ROCE %	21%	19%	17%	16%	17%	18%	17%	18%	39%	35%	23%	14%
Debtor Days	51	46	56	66	72	59	85	92	86	106	88	105
Inventory Turnover	3.25	2.95	2.31	2.16	2.20	1.70	1.42	1.09	1.84	1.19	0.86	0.82

Shareholding Pattern

Numbers in percentages

Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021
48.38	48.34	48.42	48.71	49.01	48.98	48.98	48.93	48.93	48.91	48.91	48.87
24.39	24.32	23.82	21.39	20.10	21.59	21.98	21.67	20.40	19.32	18.17	16.35
6.26	6.10	6.09	7.13	8.14	8.97	9.64	10.57	12.82	13.71	15.04	16.14
20.97	21.24	21.67	22.77	22.75	20.47	19.40	18.83	17.85	18.07	17.88	18.65

Natco Pharma Ltd

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Recent announcements

Annual reports

Credit ratings

Concalls